XBiotech (XBIT) refines disclosure on director’s private equity consulting role

Rhea-AI Filing Summary

XBiotech Inc., a British Columbia, Canada corporation listed on the NASDAQ Global Select Market under the symbol XBIT, submitted an amended current report to clarify previously described background information for one of its directors. The update concerns how Craig Rademaker’s role with private equity firms is characterized.

The company now states that Mr. Rademaker is a consultant to a number of Canadian private equity firms and that his responsibilities principally include capital markets activities. No changes to his directorship, compensation, or company financials are discussed in this update.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

true 0001626878 0001626878 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2025

XBIOTECH INC.

(Exact name of Registrant as specified in its charter)

British Columbia, Canada

(State of Incorporation)

001-37347

(Commission File Number)

N/A

(I.R.S. Employer Identification No.)

	5217 Winnebago Ln, Austin, TX	78744
	(Address of principal executive offices)	(Zip Code)

(512) 386-2900

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	XBIT	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

XBiotech Inc. (“XBiotech” or the “Company”) files this Form 8-K/A solely to clarify information regarding director Craig Rademaker’s position at the private equity firm referenced in the first sentence of the third paragraph of the June 24, 2025 Form 8-K previously filed by the Company. That sentence is restated as follows.

Mr. Rademaker is a consultant to a number of Canadian private equity firms. His responsibilities principally include capital markets activities.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 15, 2025	XBIOTECH INC.
	By:	/s/John Simard
		John Simard
		Chief Executive Officer and President

FAQ

What change does XBiotech Inc. (XBIT) report in this 8-K/A?

XBiotech Inc. reports an amendment that clarifies background information about director Craig Rademaker. The company restates one sentence to describe him as a consultant to several Canadian private equity firms focused on capital markets activities.

How is XBiotech director Craig Rademaker’s role now described?

Craig Rademaker is now described as a consultant to a number of Canadian private equity firms. The amended language explains that his responsibilities principally include capital markets activities, refining the prior description without indicating changes to his board position.

Does the XBiotech (XBIT) amendment disclose any financial results or transactions?

The amendment does not present financial results or major transactions. It is limited to clarifying descriptive information about a director’s professional role with Canadian private equity firms, specifically his focus on capital markets activities.

Is Craig Rademaker’s board position at XBiotech affected by this 8-K/A?

The filing does not state any change to Craig Rademaker’s position as a director. It only restates one background sentence to better describe his consulting work for Canadian private equity firms and his capital markets responsibilities.

On which exchange is XBiotech Inc. (XBIT) listed and what does it trade as?

XBiotech Inc. is listed on the NASDAQ Global Select Market. Its common stock, with no par value, trades under the ticker symbol XBIT, as indicated in the securities registration section of the disclosure.